Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 3Meningioma 3Prostatic Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Neuroblastoma 1Neoplasms 1Glioma 1Ganglioneuroma 1Ganglioneuroblastoma 1Disease 1Carcinoid Tumor 1Breast Neoplasms 1Breast Cancer Metastatic 1Advanced Gastroenteropancreatic Neuroendocrine Tumor 1

Interventions

Everolimus 10Octreotide 7pasireotide 5lanreotide 5gallium Ga 68 dotatate 4lutetium Lu 177 dotatate 3cabozantinib 3Sunitinib 3Nivolumab 3ganitumab 2Temozolomide 2Erlotinib Hydrochloride 2Capecitabine 2Bevacizumab 2zimberelimab 1veliparib 1telotristat ethyl 1surufatinib 1recombinant interferon alpha 2b-like protein 1pertuzumab 1pembrolizumab 1olaparib 1nintedanib 1ibrutinib 1fosbretabulin 1epothilone B 1conatumumab 1cixutumumab 1carfilzomib 1azaspirane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoid Tumor × Ga(III)-DOTATOC × Clear all
NCT02359500 2017-05-03

68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)

Icahn School of Medicine at Mount Sinai

Phase 1 Terminated
71 enrolled
EndocrineNET

Carcinoid Tumor, Disease, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡